InsiderTrades

Form 4 for ENSC Ensysce Biosciences, Inc.

Accepted 2022-05-27 00:00:00 ET · period of report 2022-05-25 · accession 0001493152-22-015294 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-05-27 2022-05-25+ ENSC Kirkpatrick Lynn CEO, Dir P - Purchase $0.5011 +97.0K 354.9K +38% +$48.6K
D 2022-05-27 2022-02-17 ENSC Kirkpatrick Lynn CEO, Dir A - Grant — +200.0K 2.52M +9% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-26 P A 27,000 $0.53 381,851 D — —
2 Common Common Stock 2022-05-25 P A 70,000 $0.49 354,851 D — —
3 Derivative Stock Option 2022-02-17 A A 200,000 — 2,516,939 D $1.40 · — to 2032-02-17 200,000 Common Stock (F1) On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.